|Bid||21.95 x 1000|
|Ask||22.63 x 2900|
|Day's Range||21.94 - 22.41|
|52 Week Range||14.52 - 23.92|
|Beta (5Y Monthly)||0.98|
|PE Ratio (TTM)||N/A|
|Earnings Date||Jul 27, 2021 - Aug 02, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||22.11|
Shares of Alkermes (NASDAQ: ALKS) climbed 17.8% in April, according to S&P Global Market Intelligence. Alkermes announced a partnership to fight ovarian cancer, reported earnings that beat Wall Street estimates, and reached an agreement with an activist hedge fund that had been agitating for changes. Early in the month, the company announced it would advance the combination of nemvaleukin -- its drug that expands tumor-killing immune cells -- with Merck's Keytruda, to phase 3 trials.
Biotech investors live and die by the binary news events generated by the drugmakers they invest in. Heron Therapeutics (NASDAQ: HRTX), for instance, is awaiting a decision from the Food and Drug Administration about its candidate HTX-011 for use in post-operative pain. Likewise, Alkermes (NASDAQ: ALKS) expects an FDA decision on its schizophrenia and bipolar treatment ALKS3831 on or before June 1.
Alkermes plc (Nasdaq: ALKS) announced today that management will participate in a virtual fireside chat at the BofA Securities 2021 Healthcare Conference on Wednesday, May 12, 2021 at 2:45 p.m. ET (7:45 p.m. BST). The presentation may be accessed under the Investors tab on www.alkermes.com and will be archived for 14 days.